NF1 mutations in conjunctival melanoma Journal Article


Authors: Scholz, S. L.; Cosgarea, I.; Süßkind, D.; Murali, R.; Möller, I.; Reis, H.; Leonardelli, S.; Schilling, B.; Schimming, T.; Hadaschik, E.; Franklin, C.; Paschen, A.; Sucker, A.; Steuhl, K. P.; Schadendorf, D.; Westekemper, H.; Griewank, K. G.
Article Title: NF1 mutations in conjunctival melanoma
Abstract: Background: Conjunctival melanoma is a potentially deadly eye tumour. Despite effective local therapies, tumour recurrence and metastasis remain frequent. The genetics of conjunctival melanomas remain incompletely understood. Methods: A large cohort of 63 conjunctival melanomas was screened for gene mutations known to be important in other melanoma subtypes by targeted next-generation sequencing. Mutation status was correlated with patient prognosis. Results: Frequent mutations in genes activating the MAP kinase pathway were identified. NF1 mutations were most frequent (n = 21, 33%). Recurrent activating mutations were also identified in BRAF (n = 16, 25%) and RAS genes (n = 12, 19%; 11 NRAS and 1 KRAS). Conclusions: Similar to cutaneous melanomas, conjunctival melanomas can be grouped genetically into four groups: BRAF-mutated, RAS-mutated, NF1-mutated and triple wild-type melanomas. This genetic classification may be useful for assessment of therapeutic options for patients with metastatic conjunctival melanoma. © 2018 Cancer Research UK.
Journal Title: British Journal of Cancer
Volume: 118
Issue: 9
ISSN: 0007-0920
Publisher: Nature Publishing Group  
Date Published: 2018-05-01
Start Page: 1243
End Page: 1247
Language: English
DOI: 10.1038/s41416-018-0046-5
PROVIDER: scopus
PUBMED: 29559732
PMCID: PMC5943412
DOI/URL:
Notes: Article -- Export Date: 1 June 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Rajmohan Murali
    219 Murali